|
|
|||||||
Letter |
Myelodysplastic syndrome (MDS), considered a pre-leukemic state, has recently been categorized as a subset of bone marrow failure syndromes. Unlike other subtypes of bone marrow failure syndromes, such as aplastic anemia or dyskeratosis congenita, little is known about genetic alterations of human telomerase in MDS, despite the fact that immune cells from patients with MDS frequently exhibit telomere attrition.
This article has been cited by other articles:
![]() |
M. Aivado, D. Spentzos, U. Germing, G. Alterovitz, X.-Y. Meng, F. Grall, A. A. N. Giagounidis, G. Klement, U. Steidl, H. H. Otu, et al. From the cover: Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease PNAS, January 23, 2007; 104(4): 1307 - 1312. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Putzki, S. Knipp, T i. Ramczykowski, S. Vago, U. Germing, H. Chr. Diener, and V. Limmroth Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosis Multiple Sclerosis, June 1, 2006; 12(3): 363 - 366. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |